The gut microbiome plays a vital role in developing and managing cancer, including diagnosis, prognosis, therapy, and remission. Recently, multi-omics and artificial intelligence advance the insights into the relationship between microbiome and cancers and their clinical application. For example, both in vivo and vitro experiments have demonstrated that some pathogenic bacteria could promote the deterioration of tumors, participate in drug metabolism and cause chemotherapy resistance. In contrast, beneficial bacteria or their consortia restored intestinal homeostasis, thus supporting the concept that patients may benefit from selective microbiota-targeting therapy. Additionally, natural products have been a rich source of compounds for drug discovery, particularly as anticancer and antimicrobial agents. Many of which are well tolerated and promising chemoprotective agents and supplements to conventional cancer therapy.
Although next generation sequencing promoted numerous studies of cancer diagnosis (especially colorectal cancer) using microbiome markers, they have not yet translated to commercial diagnostic interventions in humans. Thus, different disease controls, multi-cohort samples or meta-analysis should be considered in the research design to explore their diagnostic performance for early cancer lesions. Furthermore, the gut microbiome affects drug metabolism, cause immune disorders and chemotherapy resistance, elucidating their pathogenic mechanism or applying microbiota modulation trials will facilitate clinical treatment. During this process, ex vivo drug metabolism screen, exosomes research and designed bacterial consortia etc., will be promising directions. Finally, preclinical and clinical data demonstrated the possibility of using bacteria as new therapeutic targets. In the genomics era, functional assays and phenotypic screens, genomic and metabolomic approaches may facilitate drug development based on genetic diversity.
This special issue welcomes original research, reviews, and meta-analysis articles. The directions include but are not limited to the following:
? Applying omics technology to study the application of the microbiome and their gene markers in the early diagnosis of cancers.
? Mechanism or impact of tumor-associated pathogenic bacteria (including intratumoral microbes) on carcinogenesis, cancer progression, and therapy response.
? Microbiota modulation trials using prebiotics designed bacterial consortia or faecal microbiota transplant.
? The role of the gut microbiome in drug metabolism and the discovery of related genes or enzymes.
? Targeting cancer-related pathogenic bacteria to screen, design and develop natural products with anti-tumor and antibacterial effects.
The gut microbiome plays a vital role in developing and managing cancer, including diagnosis, prognosis, therapy, and remission. Recently, multi-omics and artificial intelligence advance the insights into the relationship between microbiome and cancers and their clinical application. For example, both in vivo and vitro experiments have demonstrated that some pathogenic bacteria could promote the deterioration of tumors, participate in drug metabolism and cause chemotherapy resistance. In contrast, beneficial bacteria or their consortia restored intestinal homeostasis, thus supporting the concept that patients may benefit from selective microbiota-targeting therapy. Additionally, natural products have been a rich source of compounds for drug discovery, particularly as anticancer and antimicrobial agents. Many of which are well tolerated and promising chemoprotective agents and supplements to conventional cancer therapy.
Although next generation sequencing promoted numerous studies of cancer diagnosis (especially colorectal cancer) using microbiome markers, they have not yet translated to commercial diagnostic interventions in humans. Thus, different disease controls, multi-cohort samples or meta-analysis should be considered in the research design to explore their diagnostic performance for early cancer lesions. Furthermore, the gut microbiome affects drug metabolism, cause immune disorders and chemotherapy resistance, elucidating their pathogenic mechanism or applying microbiota modulation trials will facilitate clinical treatment. During this process, ex vivo drug metabolism screen, exosomes research and designed bacterial consortia etc., will be promising directions. Finally, preclinical and clinical data demonstrated the possibility of using bacteria as new therapeutic targets. In the genomics era, functional assays and phenotypic screens, genomic and metabolomic approaches may facilitate drug development based on genetic diversity.
This special issue welcomes original research, reviews, and meta-analysis articles. The directions include but are not limited to the following:
? Applying omics technology to study the application of the microbiome and their gene markers in the early diagnosis of cancers.
? Mechanism or impact of tumor-associated pathogenic bacteria (including intratumoral microbes) on carcinogenesis, cancer progression, and therapy response.
? Microbiota modulation trials using prebiotics designed bacterial consortia or faecal microbiota transplant.
? The role of the gut microbiome in drug metabolism and the discovery of related genes or enzymes.
? Targeting cancer-related pathogenic bacteria to screen, design and develop natural products with anti-tumor and antibacterial effects.
